Strides Pharma Science reported a consolidated revenue of ₹12,654 million for Q1FY27, marking a 13% year-on-year increase driven by a robust 17% expansion in Ex-US markets. The US business remained steady at ₹6,282 million ($68 million), growing modestly by 4%, while the company's reported profit after tax (PAT) surged 56.7% to ₹1,655 million. This bottom-line jump was primarily fueled by a one-time exceptional gain of ₹742.07 million from the dilution of its controlling stake in Pivot Path Private Limited. Excluding this non-recurring item, operational PAT rose 8% to ₹1,231 million, demonstrating underlying resilience despite absorbing approximately ₹131 million in elevated freight and operating costs linked to geopolitical disruptions.

The Board of Directors approved the unaudited financial results on July 31, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Statutory auditors B S R & Co. LLP issued an unmodified limited review report. The company also announced that CARE Ratings upgraded its Long-Term Bank Facilities rating to CARE A+; Stable from CARE A; Positive, reflecting improved creditworthiness amidst steady cash flow generation.

Financial Performance Highlights

Strides Pharma Science's gross margin expanded by 14% year-on-year to ₹7,702 million, improving the gross margin percentage by 60 basis points to 60.9%. However, EBITDA margin contracted slightly to 18.2% from 19.5% in Q1FY26, as absolute operating costs outpaced revenue growth. The company reduced net debt by ₹119 million during the quarter, bringing the Net Debt-to-EBITDA ratio to 1.52x. Operating cash flow stood at ₹1,087 million for the quarter.

Badree Komandur, Managing Director and Group CEO, attributed the performance to investments in Ex-US markets yielding strong results. He noted that the company retained meaningful participation in Pivot Path's future growth through a five-year Master Services Agreement after unlocking ₹1,000 million in value from the divestment.

Strategic Developments and Market Outlook

In the US market, Strides Pharma Science launched two new products in Q1FY27, bringing the total number of commercialized products to 72. The company continues to rank among the top three in 37 products, contributing approximately 70% of total US revenue. However, slower-than-expected quota allocation is impacting Controlled Substances revenue growth. Management expects new product approvals in H2FY27 and aims for North America business revenue of ~$375 million by FY28. The company has filed a second Nasal Spray product (Controlled Substance) in May 2026 as part of its long-term strategy.

Ex-US markets contributed ₹5,875 million ($63 million) to revenue, growing 17% year-on-year. Strong customer advocacy and dependable supply enabled expansion in the UK and Nordics, while Africa operations delivered stellar growth through the Brands business. The company continues to add new customers in Europe and sees momentum in regulatory filings across the region.

What the Numbers Show

The divergence between 13% revenue growth and 5.40% EBITDA growth highlights the impact of macroeconomic pressures on operating efficiency. While gross margins expanded, indicating better product mix or pricing power, the compression in EBITDA margins suggests that selling, general, and administrative expenses or direct operational costs are rising faster than revenue. The strong 17% growth in Ex-US markets serves as a critical counterbalance to the steady US business, validating the company's diversification strategy. The reduction in net debt alongside healthy operational cash flows demonstrates prudent balance sheet management, positioning the company to withstand further geopolitical volatility. Additionally, the EcoVadis sustainability score improved to 68/100, a 19-point increase over the previous year.

Strides Pharma Science reported a consolidated net profit of ₹1.6 billion for Q1FY27, compared to ₹1 billion in the same quarter of the previous year, reflecting a significant year-on-year improvement in bottom-line performance. The results were discussed during the company's earnings conference call held on July 31, 2026, at 5:00 PM IST, where management provided insights into the quarterly financial outcomes and operational developments.

Q1FY27 Financial Highlights

The latest quarterly results underscore a notable improvement in profitability for Strides Pharma Science on a year-on-year basis. The following table summarises the key financial metric reported:

Earnings Conference Call Details

The Q1FY27 results were presented to investors and analysts through a scheduled earnings conference call. The management team led the discussion, offering insights into operational metrics and financial outcomes for the period. Key executives who participated in the call included:

• Badree Komandur, Managing Director & Group CEO
• Vikesh Kumar, Group CFO

The invitation for the call was issued by Manjula Ramamurthy, Company Secretary & Compliance Officer, on July 24, 2026.

Participants joined the session via webcast or through dial-in numbers available for India, the USA, the UK, Singapore, and Hong Kong. Detailed joining instructions and the formal invitation are available on the company's website at www.strides.com .

Investor Significance

This quarterly earnings disclosure is a standard regulatory practice for listed entities in India, ensuring transparency in financial reporting. The year-on-year improvement in consolidated net profit provides stakeholders with a direct measure of the company's financial progress, with management available to address queries on revenue drivers, margin trends, and other material developments from the Q1FY27 period.